We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Danaher Corporation | NYSE:DHR | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.78 | 0.32% | 246.58 | 248.0992 | 243.68 | 244.06 | 2,709,341 | 01:00:00 |
From Apr 2021 to Apr 2024
By Matt Grossman
Danaher Corp. on Thursday logged greater sales and earnings in the third quarter, including contributions from its work on Covid-19 testing and countermeasures.
The medical and diagnostics company posted earnings of $1.54 a share, up from $1.16 a share a year earlier. Net income was $1.12 billion, up from $842 billion a year ago.
Stripping out one-time items, the company posted earnings of $2.39 a share. Analysts were forecasting adjusted earnings of $2.15 a share, according to FactSet.
Danaher's sales were $7.23 billion, up from $5.88 billion in the year-ago quarter. Analysts had anticipated revenue of $7 billion.
Covid-19-related tailwinds boosted sales by 10.5% in the quarter. Excluding that and the effects of acquisitions and currency exchange, base-business core sales growth was 10% year-over-year, the company said.
Write to Matt Grossman at matt.grossman@wsj.com
(END) Dow Jones Newswires
October 21, 2021 06:28 ET (10:28 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Danaher Chart |
1 Month Danaher Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
